Clinical Trials
Perioperative durvalumab plus FLOT improves overall survival in phase 3 trial
Janjigian et alThe Lancet

In the global, randomised, double-blind, placebo-controlled, multicentre, phase 3 MATTERHORN trial evaluating perioperative therapy for resectable gastric and gastro-oesophageal junction adenocarcinoma, the addition of durvalumab to fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) improved overall survival compared with placebo plus FLOT. Based on these final trial findings, perioperative durvalumab plus FLOT establishes a new standard treatment option for patients presenting with resectable gastric or gastro-oesophageal junction adenocarcinoma.
Key Takeaways
- Perioperative durvalumab plus FLOT demonstrated improved overall survival compared with placebo plus FLOT in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
- Perioperative durvalumab combined with FLOT establishes a new standard treatment option for patients with resectable gastric and gastro-oesophageal junction adenocarcinoma.
Read the original sourceThe Lancet
